Selected outcomes
The highest grade available, six reviews in a row. Every role-based metric and KPI met or exceeded in the same years.
Twelve cases from the work
Three tests I put to any risk, system or process
Is anyone actually watching it?
Found that protocol-deviation root causes had no place in the global CTMS layout. Raised it, and the process was amended.
Does it fit the work?
Asked what monitors need for full oversight under risk-based monitoring; systems were evaluated on that basis, and my input fed the approach now in use.
Can it be followed?
Traced unreliable tumour assessments at a site to radiology reports that did not follow RECIST; trained the radiology department and verified the fix at the next visit.
From the lab bench to global systems
Cardiac development research; co-author in Nature Communications.
Phase I–III oncology monitoring in Germany and Switzerland, among the first under risk-based monitoring; twenty active sites at all times.
Germany, Switzerland and Austria; lead CRA on global studies; CTMS subject matter expert; led the regional AI capability workstream; assigned onboarding coach for incoming monitors.
Company-wide CTMS roll-out (2022–23) and a 12-month global remote site engagement and systems assignment (2025–26).
Concurrent. Brought in to support recruitment on a study through the KOL landscape and referral network; made insight documentation easier and escalated a gap in how field insight reaches study teams.
Senior individual contributor, Manager or Associate Director. Switzerland or remote.